USANA Health Sciences Faces Steep Decline Amidst Brand Underperformance
USANA Health Sciences (USNA) experienced a significant stock drop following its Q2 earnings report. The company's core direct selling division continued its predictable contraction, while its two growth brands, Hiya and Rise Wellness, showed alarming revenue declines. This led to a substantial reduction in their 2026 financial projections, prompting a re-evaluation of USNA's stock valuation.
Top Personal Loan Options for Fair Credit Borrowers in August 2026
For individuals with fair credit seeking personal loans, Investopedia has identified six leading lenders for August 2026. These institutions are more inclined to approve applicants with moderate credit scores and offer competitive terms. The evaluation involved a comprehensive review of 59 companies, focusing on various factors including borrower feedback. Patelco Credit Union was distinguished as the premier choice, recognized for its extensive repayment periods and flexible loan amounts.
Market Insights: Key Performers in Mid-Cap Value Fund's Recent Quarter
This report summarizes the performance of a mid-cap value fund during the second quarter of 2026, highlighting top-contributing companies. It focuses on the strategic roles and market successes of ON Semiconductor, Knight-Swift Transportation, and Expand Energy, detailing their impact on the fund's returns and their significance in their respective industries.
NVIDIA Maintains Strong Buy Rating Amidst AI-Driven Growth and Promising Q2 Outlook
NVIDIA Corporation (NVDA) continues to receive a Strong Buy rating due to its expected robust top-line growth and gross margin expansion in Q2, primarily fueled by AI demand. Analysts anticipate Q2 revenue of $91.85 billion and EPS of $2.08, with potential for even better results. The company's networking segment, driven by innovations like Spectrum-6, is projected to outperform computing. Despite credit risk concerns, NVDA's valuation remains attractive with a forward PEG of 0.53 and a 2030 earnings multiple of just 12.11x.
THE Process
A journey through editorial reduction. Scroll to explore
Top Personal Loan Options for Fair Credit Borrowers in August 2026
For individuals with fair credit seeking personal loans, Investopedia has identified six leading lenders for August 2026. These institutions are more inclined to approve applicants with moderate credit scores and offer competitive terms. The evaluation involved a comprehensive review of 59 companies, focusing on various factors including borrower feedback. Patelco Credit Union was distinguished as the premier choice, recognized for its extensive repayment periods and flexible loan amounts.
Market Insights: Key Performers in Mid-Cap Value Fund's Recent Quarter
This report summarizes the performance of a mid-cap value fund during the second quarter of 2026, highlighting top-contributing companies. It focuses on the strategic roles and market successes of ON Semiconductor, Knight-Swift Transportation, and Expand Energy, detailing their impact on the fund's returns and their significance in their respective industries.
NVIDIA Maintains Strong Buy Rating Amidst AI-Driven Growth and Promising Q2 Outlook
NVIDIA Corporation (NVDA) continues to receive a Strong Buy rating due to its expected robust top-line growth and gross margin expansion in Q2, primarily fueled by AI demand. Analysts anticipate Q2 revenue of $91.85 billion and EPS of $2.08, with potential for even better results. The company's networking segment, driven by innovations like Spectrum-6, is projected to outperform computing. Despite credit risk concerns, NVDA's valuation remains attractive with a forward PEG of 0.53 and a 2030 earnings multiple of just 12.11x.
Module 04
Curated Narratives
Harmony Biosciences Shifts Focus to Orexin-2 Receptor Agonist, Upgrades Stock Rating
Harmony Biosciences Holdings, Inc. has upgraded its stock rating from Sell to Hold after elevating BP-205, its orexin-2 receptor agonist, to lead the pipeline. This strategic shift indicates a renewed focus on pipeline development and more specific business development initiatives. The updated valuation reflects that most of the improvement is now incorporated into the stock price.
By Strive Masiyiwa•Aug 05, 2026
Fidus Investment: Navigating a Strong Q1 Amidst Price Appreciation
Fidus Investment (FDUS) delivered robust Q1 results, yet its recent stock surge suggests caution for new investments. The company's focus on first-lien debt and resilient software/IT portfolio, coupled with impressive NII growth and dividend coverage, highlight its solid performance. However, a 'hold' rating is maintained pending Q2 results to confirm the consistency of these strong indicators.
By Robert Kiyosaki•Aug 05, 2026
Midcap Value Fund Shows Strong Performance Amidst Market Rally
The Carillon Chartwell Mid Cap Value Fund demonstrated robust performance in the second quarter, aligning with a broad market rally across various size and style segments. The Russell Midcap Value® Index, the fund's benchmark, achieved a 13% total return, pushing its year-to-date return to 18%. Healthcare and industrials were significant contributors, while energy, consumer staples, and utilities lagged. This positive trend was observed alongside increased retail margin accounts, prime broker loans to hedge funds, and inflows into levered exchange-traded funds, indicating heightened market activity.
By Nouriel Roubini•Aug 05, 2026
Understanding Angel Investors: A Comprehensive Guide to Early-Stage Startup Funding
Angel investors provide crucial seed funding to early-stage startups in exchange for equity, offering a high-risk, high-reward investment opportunity. These individuals are typically wealthy and seek innovative ventures, often in tech or life sciences, that may not qualify for traditional financing. Their involvement can range from minimal to active, providing essential capital and sometimes mentorship to help nascent businesses grow and succeed.
By Mariana Mazzucato•Aug 05, 2026